Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas

Phase II trial with three independent strata to independently assess the effects of the association of pembrolizumab and cabozantinib in advanced sarcomas.

Trial Details

NCT ID
NCT05182164
Phase
PHASE2
Sponsor
Institut Bergonié
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Association of pembrolizumab + cabozantinib
Locations (sample)
  • Bordeaux, France|44.84124,-0.58046
  • Dijon, France|47.31344,5.01391
  • Lille, France|50.63391,3.05512
  • Lyon, France|45.74906,4.84789
  • Marseille, France|43.29695,5.38107

Key Eligibility Criteria

  • Histology: undifferentiated pleomorphic sarcoma (stratum 1), bone osteosarcoma (stratum 2), bone or extraskeletal or Ewing sarcoma (stratum 3),
  • Advanced non resectable / metastatic disease,
  • Recurrent disease or progression after standard therapy,
  • Documented progression according to RECIST criteria.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →